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Methods. We analyzed patients undergoing coronary artery bypass graft surgery at two Ohio hospitals (n [ 6,947) from 1994 to 2007. Salvage operations and patients with preoperative renal failure were excluded. Long-term outcomes and leading cause of death (cardiac, noncardiac, all cause) were derived from the US Social Security Death Index and later from Ohio Department of Health Death Index. Fifteen-year mortality cumulative incidence functions were compared for transfusion groups (yes, n [ 2,540; no, n [ 4,806) overall, and then stratified based on perioperative complications status (yes, n [ 2,638; no, n [ 4,708) . Comprehensive, 32 covariates, risk-adjusted transfusion effects were estimated by competing risk regression. Results were confirmed by propensity score adjusted analysis.
Results. Perioperative transfusions and complications occurred in 33.9% and 35.2% of patients, respectively. In all, 3,108 deaths (48.1%) have been documented (median time to death, 7.43 years). Both transfusion rates (25.6% versus 49.1%, p < 0.001) and deaths (58.2% versus 38.5%, p < 0.001) were more frequent among complications patients. Red blood cells transfusion increased intermediate to late mortality risk overall (15-year adjusted hazard ratio [AHR] 1.21, 95% confidence interval [CI]: 1.11 to 1.31), and for complications (AHR 1.24, 95% CI: 1.11 to 1.39) and no complications (AHR 1.16, 95% CI: 1.03 to 1.31). The increased mortality was true for cardiac and noncardiac etiologies (AHR 1.19, 95% CI: 1.03 to 1.36, and AHR 1.14, 95% CI: 1.01 to 1.29, respectively). Red blood cell transfusion increased mostly cardiac deaths (AHR 1.38, 95% CI: 1.14 to 1.66) among the complications group, and noncardiac mortality (AHR 1.24, 95% CI: 1.05 to 1.47) for the no complications group. A parallel propensity matched sensitivity analysis confirmed these findings.
Conclusions. Perioperative red blood cells transfusion is associated with significant adverse late death effects among both complicated patients and noncomplicated patients, principally seen between 0 and 5 years postoperatively, and is driven by both increased cardiovascular and noncardiovascular mortality. Further studies are needed to elucidate the mechanisms behind these findings, including their potential dose dependence.
(Ann Thorac Surg 2016;102:465-73) Ó 2016 by The Society of Thoracic Surgeons C ardiac surgery accounts for a substantial fraction of the total transfused blood products in the United States [1] , particularly packed red blood cells (RBC). This use of packed RBC usually aims to improve end organ oxygen delivery and subsequently clinical outcomes. Notably, despite comprehensive guidelines for perioperative erythrocyte transfusion [2] , extensive practice variation persists, in particular after coronary artery bypass graft surgery (CABG) [3] .
The rationale for transfusing patients is based on compelling evidence that untreated anemia is harmful, and hence, it reasonably follows that correcting anemia by transfusion will benefit patients. However, whereas RBC transfusions unambiguously increase blood oxygen carrying capacity, it is unclear at what level of anemia does this physiologic effect translate into improved outcomes, especially given the profound changes noted in banked blood and their potential for adverse clinical effects [4, 5] . Additionally, it is estimated that 25% to 60% of transfusions may be superfluous [6] and unnecessarily add to cost of care [7] . That led former President Clinton previously to declare that "unnecessary transfusions" are one of three major "human error" practices that require appropriate initiatives to insure they are eliminated by 2020 [8] .
Numerous studies, over more than 2 decades, have shown deleterious effects of transfusion after cardiac surgery including on intermediate to late survival [7, [9] [10] [11] [12] and long-term health-related quality of life [13] , in addition to the increased incidence of perioperative complications, some of which are directly linked to transfusion [14] [15] [16] [17] [18] [19] . Studies investigating the deleterious effects of packed RBC transfusions, in particular long term, have been limited to analyses of all-cause mortality [7, [9] [10] [11] [12] , and that has not allowed objective conclusions regarding the possible mechanisms proposed for these transfusion effects. Moreover, the interdependence between transfusion and perioperative morbidity (complications) has significantly confounded potential conclusions regarding whether transfusion, per se, is a causative factor for late postoperative cardiac surgery adverse outcomes. Indeed, none of the databases available for analysis currently includes sufficient granularity to address these limitations.
The current study aimed to mitigate these two limitations through (1) stratified subanalyses, in addition to the overall cohort, where patients having and patients not having perioperative complications after surgery are considered separately; and (2) in all cases, procuring death certificate, cause-specific mortality data, combined with using appropriate competing risk survival analysis methods, to quantify cardiac versus noncardiac late effects of RBC transfusions on CABG survival.
Patients and Methods

Patients
This investigation is a retrospective analysis of prospectively collected clinical registries collected at two Toledo, Ohio, hospitals based on the data field definitions of, and reported to, The Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database. The study was approved by the Institutional Review Boards, did not involve additional review of hospital records or patient contact, and informed consent requirement was waived.
Study subjects were restricted to primary CABG patients. Patients were excluded if they had concomitant valve or aortic surgery, emergency salvage, or preoperative renal failure. Patients were grouped and compared based on perioperative erythrocyte transfusion status (transfusion versus no transfusion). Given the potential interdependence of transfusion and postoperative morbidity, comparisons were repeated after stratifying patients as having (complication) versus not having (no complication) any of the postoperative complications in the STS database. The operative technique and perioperative management were previously described [20] .
Cardiopulmonary bypass (97%) and aortocoronary grafting (99%) were used in most patients. Multiple artery grafting was utilized extensively and was adjusted for in the analysis. A blood conservation protocol was followed, although transfusion triggers were at the physician's discretion. Leukocyte-poor blood was used exclusively during the later years of the study series and preferentially during the earlier years.
Outcome
The primary endpoint was all-cause mortality, complemented with secondary analyses based on cardiac or noncardiac death. Perioperative or 30-day mortality was considered to be surgery related and hence was considered a cardiac death. Ninety-five percent of patients with perioperative death also had a complication and were allocated into the complication subcohort. Long-term survival data were obtained from our service follow-up, routine twice-annual searches of US Social Security Death Index database (2011), and complemented by cross-checking with the Ohio State Death Registry (January 1994 to December 2013). Leading cause of death was extracted from death certificates in the Ohio State Death Registry using International Classification of Diseases (ICD), ninth revision (1996 to 1998) and 10th revision (1999 to 2013) codes. Cardiac mortality was defined by ICD 10 codes I00 to I09, I11, I13, and I20 to I51; and their corresponding ICD 9 codes 390 to 398, 402, 404, and 410 to 429. Coronary heart disease mortality was identified using ICD 10 codes I20 to I25 and their corresponding ICD 9 codes 410 to 414 and 429 [21] .
Statistical Analysis
Continuous variables were expressed as mean AE SD and compared using the independent Student's t test or Mann-Whitney U test based on normality. Categoric variables were expressed as counts (percentages) and compared by the c 2 test. Fifteen-year cumulative incidence of mortality based on all-cause, cardiac, and noncardiac death were estimated by survival analysis accounting for competing risks, and always compared for transfusion group versus no-transfusion group. Transfusion and no-transfusion matched cohorts were derived using separate complications and no-complications propensity score models (see supplemental data). Unadjusted hazard ratio (HR) and covariate-adjusted hazard ratio (AHR) adjusted to all factors in Table 1 Table 2 shows cause-specific mortality stratified by complications and transfusion status. Figure 1 , top, shows unadjusted 15-year cumulative allcause, cardiac, and noncardiac death incidence functions, and these were consistently worse among transfused patients (all, p ¼ 0.000). Figure 1 , middle and bottom, show similar transfusion effect (all significant) in both the complications group and no-complications group, respectively. The corresponding unadjusted HR and covariate AHR for all of these nine comparisons are shown in Figure 2 , left. Briefly, all-cause mortality transfusion related 0-to 15-year AHR was 1.22 (95% CI: 1.13 to 1.32), and was slightly greater for complications patients (1.25, 95% CI: 1.12 to 1.40) versus nocomplications patients (1.19, 95% CI: 1.06 to 1.34). Timesegmented analysis showed that this transfusion effect is predominantly an early 0 to 5 years effect and is gradually reduced to essentially no effect by 10 years (Table 3) .
A total of 1,916 propensity-matched transfusion and no-transfusion pairs (complications, n ¼ 859, and no complications, n ¼ 1,057) were identified (supplemental Table S-1; all matched cumulative incidence function comparisons are shown in supplemental Fig S-1) . Matchadjusted AHR generally confirmed the primary covariateadjusted analysis (Fig 2, right; Table 3 ).
The matched analysis showed relatively lower average number needed to treat values of 18 to 21 for the complications group compared with 23 to 59 for the no-complications group (Table 4) . Alternatively, withholding transfusions resulted in more modest added years of life (DT) in the no-complications group (DT ¼ 0.5 years) compared with the complications group (DT ¼ 1.4 1.14 to 1.66) among complications patients and noncardiac mortality (AHR 1.24, 95% CI: 1.05 to 1.47) among nocomplications patients. Lastly, our study indicated that the packed RBC adverse effects on survival were principally focused in the 5 postoperative years and gradually decline thereafter. Our findings for CABG patients add to growing evidence regarding transfusion risk for cardiac surgery [6] [7] [8] [9] [10] , the critically ill [22] , and myocardial infarction [23] . In cardiac surgery, increased rates of infectious [7] and pulmonary [14] complications as well as atrial fibrillation [15] have been observed among patients receiving transfusions. These complications may be independently associated with diminished survival, which confounds the transfusionsurvival association. To our knowledge, this study represents the first report of an association between transfusions and mortality among patients stratified by perioperative complications. Our finding of increased long-term mortality risk for patients without any perioperative complications strongly suggests that it is the transfusion itself, rather than the identified complications, that largely drive increased risk of death among CABG patients, in agreement with most other reports. Ferraris and colleagues [24] , although not focusing on perioperative complications per se, found an increased transfusion mortality risk only for lowrisk surgical patients while finding no such increased risk for high-risk patients. Mohnle and colleagues [25] reported a transfusion-associated increased morbidity for low-and intermediate-risk CABG patients. These investigators, however, studied only acute, inhospital outcomes and focused only on patients without intraoperative complications [25] . We have previously reported that blood transfusions are associated with a 21% higher risk coronary artery graft failure [18] , a possible mechanism for the observed increased mortality in the current analysis. Indirect supportive evidence for this hypothesis is that a similar increased risk of death was not noted among patients undergoing non-CABG cardiac valve operations [26] . If this is a plausible etiology, we hypothesized that the risk of cardiac deaths should be elevated preferentially over noncardiac deaths among CABG patients. To that end, we stratified the principal cause of death in the study group into either a cardiac or noncardiac etiology based on death certificate data reported to the Ohio Department of Health Death Index Database. Contrary to our hypothesis, our findings identified an equally high risk of cardiac and noncardiac death risk in the overall study cohort (AHR 1.19, 95% CI: 1.03 to 1.36, and AHR 1.14, 95% CI: 1.01 to 1.29, respectively; Fig 2) . The risk of cardiac death was highest, however, among complications patients who received transfusions (AHR 1.38, 95% CI: 1.14 to 1.66), and was higher than the risk of cardiac death in the transfused no-complications cohort (AHR 0.96, 95% CI: 0.79 to 1.22) . This finding suggests that although premature graft failure may in part account for the increased risk of cardiac death, other mechanisms must also be at play in the increased risk of noncardiac death.
Although several mechanisms have been postulated to account for the transfusion increased acute mortality risk, with immune mechanisms thought to be the principal drivers [27] , the etiologic basis of the long-term transfusion noncardiac mortality risk is unknown. Klein [28] , noting that transfusion-associated allogeneic lymphocytes are detected in the recipient's circulation for as long as a year after transfusion, suggested that persistent As we are unaware of other studies focusing on the specific cause of death behind the transfusion-associated increased mortality risk, these considerations must remain speculative, and this subject needs to be addressed by future studies.
We found that the overall transfusion-associated risk of death over the entire 15-year study was largely driven by the increased risk of death in the 0-to 5-year postoperative period (HR 1.35, 95% CI: 1.18 to 1.55; Table 3 ). Thereafter, the mortality risk systematically declined between 5 and 10 years postoperatively, becoming nonsignificant in the 10-to 15-year postoperative period. This pattern of risk confirms earlier findings [7, 11] . In an earlier analysis [9] , we noted a biphasic death hazard, with a short-term large increase in mortality within 6 months postoperatively, followed by a smaller increase in, but sustained, mortality risk as long as 5 years postoperatively. Koch and coworkers [11] found a similar early (6 months postoperatively) mortality risk. Murphy and associates [7] noted an even earlier and higher transfusion mortality risk (HR 6.69, 95% CI: 3.66 to 15.1) within 30 days of surgery, and operative death risk with a progressive decline and plateauing at 1 year postoperatively. This general agreement regarding the early high mortality risk that declines with time may be indirect evidence for the "two hit" mechanism of transfusions' mortality risk. The "first hit" associated with the trauma and acute inflammatory effects of the index operation is further amplified by the additional "second hit" of the transfusion-mediated inflammatory response during this vulnerable perioperative period, giving rise to the elevated high early risk of mortality. As this "perfect storm" of inflammation resolves, the mortality risk declines and becomes driven by the long-term, transfusiondriven immunomodulation.
We analyzed the number of patients needed to treat, with the treatment being considered avoidance of transfusion (Table 4) . We found that this was generally lower in the complications cohort versus the nocomplications cohort and ranged from 18 to 59 patients needing to avoid a transfusion to prevent one overall, cardiac or noncardiac, death. Therefore, if the transfusion rate in the STS database dropped to the 33.9% noted in this study from its current 45% rate nationally among 144,940 isolated 2014 CABG patients, between 266 and 878 lives could be saved by avoiding transfusion. Similarly, the additional years of survival conferred by avoiding transfusion was higher for the complications cohort versus the no-complications cohort. Both findings are suggestive that avoidance of transfusion is particularly beneficial for patients having a perioperative complication, an important observation given the higher transfusion rate among patients with complications [17] . As we are unable to identify the chronology between transfusions and complications (neither the transfusions nor the complications are time stamped in the STS database), it is difficult to assess the value of this observation in guiding the clinician facing the conundrum of the optimal transfusion practice with complicated patients.
The limitations of our study include its retrospective, observational nature, giving rise to potential confounding due to patient selection bias. Although we used several statistical tools to minimize confounding, these processes were necessarily limited to the factors included in the STS database. Given the increasing complexity of cardiac surgical patients, nuances of patient demographics, and the specific chronology of clinically important postoperative events, relevant factors may not have been included. The accuracy of the principal cause of death depends on death certificate data as entered into the Ohio Department of Health Death Index, and was missing for 18% of all recorded deaths. Furthermore, we did not assess the dose dependence of the transfusion risk, but rather studied transfusion as a binary variable. Also, the age of transfused blood and potential varying effects are unavailable to us. Perhaps most important, our study did not control for either the degree of preoperative anemia nor the lowest level of hematocrit on cardiopulmonary bypass, an important consideration given previous observations that the combination of anemia and transfusion carry the highest risk of adverse outcomes [10] . Given that the overwhelming majority of our patients underwent CABG on pump, our results may not be generalizable to patients undergoing off-pump surgery. Finally, we did not specifically assess the impact of transfusions on patients with complications that are specifically associated with increased long-term mortality versus short-term mortality, as specified by Gao and colleagues [29] .
In conclusion, our data provide further evidence of an independent transfusion-associated increased risk of long-term cardiac and noncardiac death after CABG, particularly in the first 5 postoperative years, and is seen even among patients without any perioperative complications. Further studies are needed to provide guidance for clinicians confronting anemic patients as to what degree of anemia, when corrected by a homologous transfusion, enhances rather than worsens clinical outcomes. SCHWANN 
